- Home
- MFC vs CRNX Comparison
MFC vs CRNX Comparison
Compare MFC & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFC
- CRNX
- Stock Information
- Founded
- MFC 1887
- CRNX 2008
- Country
- MFC Canada
- CRNX United States
- Employees
- MFC N/A
- CRNX N/A
- Industry
- MFC Life Insurance
- CRNX Biotechnology: Pharmaceutical Preparations
- Sector
- MFC Finance
- CRNX Health Care
- Exchange
- MFC Nasdaq
- CRNX Nasdaq
- Market Cap
- MFC 49.3B
- CRNX 2.8B
- IPO Year
- MFC 1999
- CRNX 2018
- Fundamental
- Price
- MFC $31.45
- CRNX $29.44
- Analyst Decision
- MFC Strong Buy
- CRNX Strong Buy
- Analyst Count
- MFC 2
- CRNX 10
- Target Price
- MFC $45.50
- CRNX $75.00
- AVG Volume (30 Days)
- MFC 2.3M
- CRNX 641.8K
- Earning Date
- MFC 08-06-2025
- CRNX 08-07-2025
- Dividend Yield
- MFC 3.81%
- CRNX N/A
- EPS Growth
- MFC 14.95
- CRNX N/A
- EPS
- MFC 1.85
- CRNX N/A
- Revenue
- MFC $20,887,744,800.00
- CRNX $760,000.00
- Revenue This Year
- MFC $35.15
- CRNX $402.12
- Revenue Next Year
- MFC $5.64
- CRNX $770.88
- P/E Ratio
- MFC $17.01
- CRNX N/A
- Revenue Growth
- MFC 9.27
- CRNX N/A
- 52 Week Low
- MFC $23.30
- CRNX $24.10
- 52 Week High
- MFC $33.07
- CRNX $62.53
- Technical
- Relative Strength Index (RSI)
- MFC 48.84
- CRNX 42.12
- Support Level
- MFC $31.19
- CRNX $28.34
- Resistance Level
- MFC $32.44
- CRNX $30.85
- Average True Range (ATR)
- MFC 0.53
- CRNX 1.10
- MACD
- MFC 0.01
- CRNX -0.24
- Stochastic Oscillator
- MFC 50.99
- CRNX 25.52
About MFC Manulife Financial Corporation
Manulife Financial provides life insurance, annuities, and asset management products to individuals and group customers in Canada, the United States, and Asia. Its investment management business contributes approximately 20% of its earnings and has around CAD 1.05 trillion in assets under management and administration as of the end of 2023. The US business, which primarily operates under the John Hancock brand, contributes about 27% of earnings and is mainly focused on providing insurance products for estate, business, and income protection. The Asia segment provides insurance products and insurance-based wealth accumulation products in over 11 countries and contributes around 30% of earnings. The Canadian business segment contributes approximately 23% of earnings.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.